Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic.

ABSTRACT:

SUBMITTER: Mizuashi M 

PROVIDER: S-EPMC12439310 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature